Catalio Capital Management LP Takes $6.68 Million Position in Olema Pharmaceuticals, Inc. $OLMA

Catalio Capital Management LP purchased a new stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) during the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 267,058 shares of the company’s stock, valued at approximately $6,676,000.

Several other institutional investors and hedge funds have also recently modified their holdings of OLMA. Siren L.L.C. acquired a new position in shares of Olema Pharmaceuticals during the 4th quarter valued at about $82,518,000. Cormorant Asset Management LP acquired a new position in shares of Olema Pharmaceuticals during the 4th quarter valued at about $68,750,000. RA Capital Management L.P. acquired a new position in shares of Olema Pharmaceuticals during the 4th quarter valued at about $65,000,000. Bain Capital Life Sciences Investors LLC boosted its position in shares of Olema Pharmaceuticals by 24.3% during the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 8,508,641 shares of the company’s stock valued at $212,716,000 after acquiring an additional 1,664,687 shares during the last quarter. Finally, Polar Capital Holdings Plc acquired a new position in shares of Olema Pharmaceuticals during the 4th quarter valued at about $34,511,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Olema Pharmaceuticals Trading Up 2.7%

NASDAQ OLMA opened at $9.44 on Thursday. The firm’s 50-day moving average is $13.62 and its two-hundred day moving average is $20.16. Olema Pharmaceuticals, Inc. has a 12 month low of $3.90 and a 12 month high of $36.26. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.88 and a quick ratio of 10.88. The stock has a market capitalization of $824.58 million, a P/E ratio of -4.67 and a beta of 1.98.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its earnings results on Tuesday, May 12th. The company reported ($0.52) EPS for the quarter, meeting analysts’ consensus estimates of ($0.52). On average, sell-side analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on OLMA shares. Wolfe Research started coverage on shares of Olema Pharmaceuticals in a research report on Friday, March 27th. They set a “peer perform” rating on the stock. Oppenheimer reissued an “outperform” rating on shares of Olema Pharmaceuticals in a research report on Monday, March 9th. TD Cowen reissued a “buy” rating on shares of Olema Pharmaceuticals in a research report on Monday, March 9th. Citigroup upped their target price on shares of Olema Pharmaceuticals from $60.00 to $62.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. Finally, Jefferies Financial Group started coverage on shares of Olema Pharmaceuticals in a research report on Thursday, March 19th. They issued a “buy” rating and a $40.00 target price on the stock. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Olema Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.10.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.